Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06613425

Clinical Study of Combined Platelet Transfusion

Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction. Due to various factors, it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice. When ABO-compatible platelets cannot be obtained, plasma-reduced platelets, platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions. The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hematologic Diseases Hemic and Lymphatic Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

About this study

Combined platelet transfusion is a single-arm, open, prospective, non-inferiority study initiated by researchers. Patients with hematological diseases who were admitted to the research unit and applied for platelet transfusion within two years were included in the study after informed consent. When the subjects applied for platelet transfusion during the study period, ABO homotype platelet transfusion was preferred. When there was no ABO homotype platelet in the inventory, ABO primary and secondary side compatible combined platelet transfusion was given. The study period was 2 years, including 15 months of enrollment, 6 months of treatment, and 3 months of follow-up after the end of the treatment period

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Aged 18-65 years; 2. Disease treatment in the research hospital; 3. Applied for platelet transfusion therapy.

Exclusion criteria

  • 1. One month before the start of this study, he participated in other clinical trials of drugs and instruments related to platelet transfusion efficacy; 2. Without platelet transfusion indications; 3. Only received platelet transfusion in the outpatient department and left the hospital without efficacy evaluation after transfusion; 4. Gave up platelet transfusion therapy for any reason after enrollment; 5. Transferred or discharged from hospital for any reason before platelet transfusion after enrollment; 6. Did not receive combined platelet transfusion during the 6-month treatment period after enrollment

Treatment and study plan

Combined platelets

Combination Product

1 therapeutic dose combined platelet contained no less than 2.5 ×10^11 platelets as a quality standard.

Primary outcomes

  1. Efficacy evaluation of combined platelet transfusion

    Time frame: From the start of infusion of combined platelets to 6 months later

    The platelet count was measured before blood transfusion and 1 hour and 24 hours after blood transfusion, and the WHO bleeding grade was recorded. The platelet incremental correction index ( CCI ) was calculated at 1 hour and 24 hours after infusion. CCI > 7.5 at 1 hour, CCI > 4.5 at 24 hours, or the control or improvement of WHO bleeding symptoms after infusion were effective for infusion.

    CCI = ( PLT after infusion-PLT before infusion ) × body surface area ( m2 ) × 1000 / total platelet count ( × 1011 ), body surface area = 0.0061 × height ( cm ) + 0.0128 × weight ( Kg ) - 0.1529.

    PPR ( % ) = ( PLT after infusion-PLT before infusion ) × blood volume ( L ) × 100 % / total platelet count × 2 / 3, blood volume = 0.07 × body weight ( Kg ).

Secondary outcomes

  1. Adverse reactions of blood transfusion

    Time frame: From the start of infusion of combined platelets to 6 months later

    During and after blood transfusion, the occurrence time, type, treatment and recovery time of adverse reactions of blood transfusion were collected and recorded, as well as the occurrence time, type, treatment and recovery time of adverse events of blood transfusion.

  2. Safety evaluation of combined platelet transfusion

    Time frame: From the start of infusion of combined platelets to 6 months later

    Blood transfusion-related infectious markers ( HBsAg, HBV DNA, anti-HCV, HCV RNA, HIV Ag / Ab, HIV RNA, anti-TP ) were detected before and after the last blood transfusion.

  3. Platelet antibody screening

    Time frame: From the start of infusion of combined platelets to 6 months later

    Platelet antibodies of the subjects were screened before blood transfusion and at the end of the intermediate follow-up period during infusion.

  4. Adverse events of blood transfusion

    Time frame: From the start of infusion of combined platelets to 6 months later

    The occurrence of adverse transfusion events in the whole process of combined platelet transfusion : time, place, type, measures and consequences.

  5. Waiting time for platelet transfusion

    Time frame: From the start of infusion of combined platelets to 6 months later

    The time from the clinical submission of platelet transfusion application to the start of platelet transfusion

  6. Interval time, frequency and total amount of platelet transfusion

    Time frame: From the start of infusion of combined platelets to 6 months later

    The interval time, frequency and total amount of platelet transfusion in the enrolled group were recorded.

  7. Bleeding adverse events during hospitalization

    Time frame: From the start of infusion of combined platelets to 6 months later

    The number of bleeding, symptoms and treatment measures during hospitalization were recorded.

Study contacts

Contact information is provided by the study sponsor or research team.

zhang li

CONTACT

[email protected]

+86 13982283001

Sponsors and collaborators

Lead sponsor

The General Hospital of Western Theater Command

Other

Registry information

Official study title

Combined Platelet Transfusion:A Single-arm, Open, Prospective, Non-inferiority Clinical Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 26, 2024
Registry last updated
Sep 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.